Repligen restates financials for 2023-2024 due to $17.3M revenue timing error; material weakness identified

REPLIGEN CORP

Restatement covers Q1'23 through Q2'24; $17.3M payment from cancelled COVID orders was mis-timed.
Impact: Q1'23 revenue overstated by $17.3M; FY'23 revenue overstated by $6.6M; H1'24 understated by $6.6M.
Material weakness identified in internal control over revenue recognition; no fraud or misconduct.
2024 revenue guidance reaffirmed and updated to $627M-$642M due to timing shift; total revenue unchanged.
No impact on cash, operations, or strategic outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.